Business of Bio Speaker Series @ The BioPark

Thursday, November 8, 2012 at 10:30am to 12:00pm

801 W. Baltimore Street, Baltimore, MD 21201

"Biotech Fundraising in Challenging Times – Working with Strategic Investors and Partners"

GlycoMimetics President & CEO Rachel King, a veteran of previous biotech startups, big pharma and the VC world, will discuss challenges and changing players in the current life science fundraising environment, her experiences in working with strategic investors such as Novartis and Genzyme, and how best to work with big pharma partners.
With Rachel's multi-dimensional life sciences industry background and hands-on experience in her current role at GlycoMimetics, this is a not-to-be-missed session for any biotech leader exploring various funding and partnering opportunities in today's environment.

About the speaker:
Rachel K. King, Chief Executive Officer & Founder, GlycoMimetics,Inc.
Before co-founding GlycoMimetics, Mrs. King was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation. Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. (GTI) from the company’s startup phase, through its IPO and later acquisition by Novartis. There she held various roles, including serving as the company’s CEO. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston. She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School. Mrs. King currently serves as Vice Chair of the Board of the Biotechnology Industry Association (BIO). At BIO, she is also on the Executive Committee and is a former Chair of the Emerging Companies Governing Body. She is also a Member of the Maryland Life Sciences Advisory Board appointed by Governor Martin O’Malley and a Board Member of the MDBio Foundation.

About GlycoMimetics, Inc.
GlycoMimetics is a privately held clinical-stage biotechnology company using novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs. Since the company’s inception in 2003, GlycoMimetics has developed a robust, diversified product pipeline. More info at

The Program:
10:30-11:30am: Presentation
11:30am-Noon: Q&A Session
Noon-1:00pm: Informal Lunch Networking Session

Hosted by the University of Maryland BioPark.



Recent Activity

People Going

Getting Here